Home » GAO Criticizes FDA for Allowing Momenta Scientist to Assist Agency
GAO Criticizes FDA for Allowing Momenta Scientist to Assist Agency
The Government Accountability Office (GAO) is criticizing the FDA for allowing a scientist from Momenta Pharmaceuticals to voluntarily assist the agency during its handling of the tainted heparin crisis in 2008. In a recent report, the GAO says that the FDA failed to consider that allowing Momenta to help with the crisis while still awaiting action on its generic version of Sanofi-Aventis’ blood-thinner Lovenox (enoxaparin sodium), a low-molecular weight heparin, could “undermine the public perception of FDA’s management of the heparin crisis.”
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May